Generic drug: blinatumomab
Brand name: Blincyto
What is Blincyto (blinatumomab), and how does it work?
Blincyto (blinatumomab) for injection is a bispecific CD19-directed CD3 T- cell engager indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
What are the side effects of Blincyto?
WARNING
CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES
- Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving Blincyto. Interrupt or discontinue Blincyto as recommended.
- Neurological toxicities, which may be severe, life-threatening, or fatal, occurred in patients receiving Blincyto. Interrupt or discontinue Blincyto as recommended.
Common side effects of Blincyto include:
- fever
- headache
- swelling of the extremities
- nausea
- tremor
- rash
- constipation
- fever accompanying low levels of white blood cells (febrile neutropenia), and
- low levels of potassium in the blood (hypokalemia)
- anemia
- low platelet levels in the blood
- low white blood cell count
- irregular heartbeats (arrhythmia)
- diarrhea
- abdominal pain
- vomiting
- fatigue
- chills
- chest pain
- infections
- weight gain
- decreased appetite
- back pain
- pain in extremities
- bone pain
- joint pain
- dizziness
- insomnia
- cough
- shortness of breath
- nosebleeds
- high or low blood pressure (hypertension or hypotension)
What is the dosage for Blincyto?
Treatment Of MRD-Positive B-Cell Precursor ALL
- A treatment course consists of 1 cycle of Blincyto for induction followed by up to 3 additional cycles for consolidation.
- A single cycle of treatment of Blincyto induction or consolidation consists of 28 days of continuous intravenous infusion followed by a 14-day treatment-free interval (total 42 days).
- See Table 1 for the recommended dose by patient weight and schedule. Patients weighing 45 kg or more receive a fixed-dose. For patients weighing less than 45 kg, the dose is calculated using the patient’s body surface area (BSA).
Table 1. Recommended Blincyto Dose and Schedule for the Treatment of MRD-positive B-cell Precursor ALL
Cycle | Patients Weighing 45 kg or More (Fixed-dose) |
Patients Weighing Less Than 45 kg (BSA-based dose) |
Induction Cycle 1 | ||
Days 1-28 | 28 mcg/day | 15 mcg/m2/day (not to exceed 28 mcg/day) |
Days 29-42 | 14-day treatment-free interval | 14-day treatment-free interval |
Consolidation Cycles 2-4 | ||
Days 1-28 | 28 mcg/day | 15 mcg/m2/day (not to exceed 28 mcg/day) |
Days 29-42 | 14-day treatment-free interval | 14-day treatment-free interval |
- Hospitalization is recommended for the first 3 days of the first cycle and the first 2 days of the second cycle. For all subsequent cycle starts and re-initiations (e.g., if treatment is interrupted for 4 or more hours), supervision by a healthcare professional or hospitalization is recommended.
- Premedicate with prednisone or equivalent for MRD-positive B-cell Precursor ALL
- For adult patients, premedicate with prednisone 100 mg intravenously or equivalent (e.g., dexamethasone 16 mg) 1 hour prior to the first dose of Blincyto in each cycle.
- For pediatric patients, premedicate with 5 mg/m2 of dexamethasone, to a maximum dose of 20 mg, prior to the first dose of Blincyto in the first cycle and when restarting an infusion after an interruption of 4 or more hours in the first cycle.
- For administration of Blincyto:
- See Section 2.5 for infusion over 24 hours or 48 hours.
- See Section 2.6 for infusion over 7 days using Bacteriostatic 0.9% Sodium Chloride Injection, USP (containing 0.9% benzyl alcohol). This option is available for patients weighing 22 kg or more. It is not recommended for use in patients weighing less than 22 kg.
Treatment Of Relapsed Or Refractory B-Cell Precursor ALL
- A treatment course consists of up to 2 cycles of Blincyto for induction followed by 3 additional cycles for consolidation and up to 4 additional cycles of continued therapy.
- A single cycle of treatment of Blincyto induction or consolidation consists of 28 days of continuous intravenous infusion followed by a 14-day treatment-free interval (total 42 days).
- A single cycle of treatment of Blincyto continued therapy consists of 28 days of continuous intravenous infusion followed by a 56-day treatment-free interval (total 84 days).
- See Table 2 for the recommended dose by patient weight and schedule. Patients weighing 45 kg or more receive a fixed-dose and for patients weighing less than 45 kg, the dose is calculated using the patient’s BSA.
Table 2. Recommended Blincyto Dose and Schedule for the Treatment of Relapsed or Refractory B-cell Precursor ALL
Cycle | Patients Weighing 45 kg or More (Fixed-dose) |
Patients Weighing Less Than 45 kg (BSA-based dose) |
Induction Cycle 1 | ||
Days 1-7 | 9 mcg/day | 5 mcg/m2/day (not to exceed 9 mcg/day) |
Days 8-28 | 28 mcg/day | 15 mcg/m2/day (not to exceed 28 mcg/day) |
Days 29-42 | 14-day treatment-free interval | 14-day treatment-free interval |
Induction Cycle 2 | ||
Days 1-28 | 28 mcg/day | 15 mcg/m2/day (not to exceed 28 mcg/day) |
Days 29-42 | 14-day treatment-free interval | 14-day treatment-free interval |
Consolidation Cycles 3-5 | ||
Days 1-28 | 28 mcg/day | 15 mcg/m2/day (not to exceed 28 mcg/day) |
Days 29-42 | 14-day treatment-free interval | 14-day treatment-free interval |
Continued Therapy Cycles 6-9 | ||
Days 1-28 | 28 mcg/day | 15 mcg/m2/day (not to exceed 28 mcg/day) |
Days 29-84 | 56-day treatment-free interval | 56-day treatment-free interval |
- Hospitalization is recommended for the first 9 days of the first cycle and the first 2 days of the second cycle. For all subsequent cycle starts and re-initiation (e.g., if treatment is interrupted for 4 or more hours), supervision by a healthcare professional or hospitalization is recommended.
- Premedicate with dexamethasone:
- For adult patients, premedicate with 20 mg of dexamethasone 1 hour prior to the first dose of Blincyto of each cycle, prior to a step dose (such as Cycle 1 Day 8), and when restarting an infusion after an interruption of 4 or more hours.
- For pediatric patients, premedicate with 5 mg/m2 of dexamethasone, to a maximum dose of 20 mg, prior to the first dose of Blincyto in the first cycle, prior to a step dose (such as Cycle 1 Day 8), and when restarting an infusion after an interruption of 4 or more hours in the first cycle.
- For administration of Blincyto:
- See Section 2.5 for infusion over 24 hours or 48 hours.
- See Section 2.6 for infusion over 7 days using Bacteriostatic 0.9% Sodium Chloride Injection, USP (containing 0.9% benzyl alcohol). This option is available for patients weighing 22 kg or more. It is not recommended for use in patients weighing less than 22 kg.
Dosage Modifications For Adverse Reactions
If the interruption after an adverse reaction is no longer than 7 days, continue the same cycle to a total of 28 days of infusion inclusive of days before and after the interruption in that cycle. If an interruption due to an adverse reaction is longer than 7 days, start a new cycle.
Table 3. Dosage Modifications for Adverse Reactions
Adverse Reaction | Grade* | Patients Weighing 45 kg or More | Patients Weighing Less Than 45 kg |
Cytokine Release Syndrome (CRS) |
Grade 3 |
|
|
Grade 4 | Discontinue Blincyto permanently. Administer dexamethasone as instructed for Grade 3 CRS. | ||
Neurological Toxicity | Seizure | Discontinue Blincyto permanently if more than one seizure occurs. | |
Grade 3 | Withhold Blincyto until no more than Grade 1 (mild) and for at least 3 days, then restart Blincyto at 9 mcg/day. Escalate to 28 mcg/day after 7 days if the adverse reaction does not recur. If the adverse reaction occurred at 9 mcg/day, or if the adverse reaction takes more than 7 days to resolve, discontinue Blincyto permanently. | Withhold Blincyto until no more than Grade 1 (mild) and for at least 3 days, then restart Blincyto at 5 mcg/m2/day. Escalate to 15 mcg/m2/day after 7 days if the adverse reaction does not recur. If the adverse reaction occurred at 5 mcg/m2/day, or if the adverse reaction takes more than 7 days to resolve, discontinue Blincyto permanently. | |
Grade 4 | Discontinue Blincyto permanently. | ||
Other Clinically Relevant Adverse Reactions | Grade 3 | Withhold Blincyto until no more than Grade 1 (mild), then restart Blincyto at 9 mcg/day. Escalate to 28 mcg/day after 7 days if the adverse reaction does not recur. If the adverse reaction takes more than 14 days to resolve, discontinue Blincyto permanently. | Withhold Blincyto until no more than Grade 1 (mild), then restart Blincyto at 5 mcg/m2/day. Escalate to 15 mcg/m2/day after 7 days if the adverse reaction does not recur. If the adverse reaction takes more than 14 days to resolve, discontinue Blincyto permanently. |
Grade 4 | Consider discontinuing Blincyto permanently. | ||
* Based on the Common Terminology Criteria for Adverse Events (CTCAE). Grade 3 is severe, and Grade 4 is life-threatening. |

SLIDESHOW
Signs of Cancer in Men: Could it Be Cancer? See SlideshowWhat drugs interact with Blincyto?
- No formal drug interaction studies have been conducted with Blincyto.
- Initiation of Blincyto treatment causes transient release of cytokines that may suppress CYP450 enzymes.
- The highest drug-drug interaction risk is during the first 9 days of the first cycle and the first 2 days of the second cycle in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index.
- In these patients, monitor for toxicity (e.g., warfarin) or drug concentrations (e.g., cyclosporine).
- Adjust the dose of the concomitant drug as needed.
Is Blincyto safe to use while pregnant or breastfeeding?
- Based on its mechanism of action, Blincyto may cause fetal harm, including B-cell lymphocytopenia, when administered to a pregnant woman.
- There are no data on the use of Blincyto in pregnant women.
- There is no information regarding the presence of blinatumomab in human milk, the effects on the breastfed infant, or the effects on milk production.
- Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in breastfed infants from Blincyto, including B-cell lymphocytopenia, advise patients not to breastfeed during treatment with Blincyto and for at least 48 hours after the last dose.
Latest Cancer News
Daily Health News
Trending on MedicineNet
Summary
Blincyto (blinatumomab) for injection is a bispecific CD19-directed CD3 T- cell engager indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Serious side effects of Blincyto include Cytokine Release Syndrome (CRS) and neurological toxicities.
Multimedia: Slideshows, Images & Quizzes
-
Cancer: Guide to Leukemia
Learn about the common types and stages of leukemia, who gets it, symptoms, tests, treatments, and more. People with blood cancer...
-
Leukemia Quiz: Test Your Medical IQ
What do you know about leukemia? Did you know there are different types? What are the symptoms? Take the Leukemia Quiz and test...
Related Disease Conditions
-
Leukemia
Leukemia is a type of cancer of the blood cells in which the growth and development of the blood cells are abnormal. Strictly speaking, leukemia should refer only to cancer of the white blood cells (the leukocytes) but in practice it can apply to malignancy of any cellular element in the blood or bone marrow, as in red cell leukemia (erythroleukemia).
-
What Is the Life Expectancy of a Person With Leukemia?
Leukemia is a group of cancers of the blood affecting the white blood cells. White blood cells are the infection-fighting cells of the body. In adults, leukemia is most common in people older than 55 years, with the average age of diagnosis being 66 years. It is also one of the most common cancers in children and adults younger than 20 years. The survival rate is higher for younger people.
-
How Does Leukemia Kill?
Leukemia is a cancer of the white blood cells of the bone marrow. Patients with leukemia have an over-production of a particular blood cell type in the body, the white blood cells (cells that fight infection, and provide immunity).
-
Survival Rate for Acute Lymphoblastic Leukemia
The prognosis depends on the type of leukemia, the extent of the disease, age of the patient, and the general condition of the patient. Some patients can go into complete remission. The average five-year survival rate of leukemia is 60-65%.
-
Leukemia: Signs, Symptoms, And Complications
Leukemia results when the genetic material (DNA) of a single cell in the bone marrow transforms, this is called a mutation. A mutated cell does not perform body function, but it eats away the nutrition meant for the normal cells.
-
Childhood Acute Lymphoblastic Leukemia (ALL)
Childhood acute lymphoblastic leukemia is the most common type of cancer in children. Symptoms and signs include fever, easy bruising, bone or joint pain, weakness, loss of appetite, and painless lumps in the neck, underarm, stomach, or groin. Treatment depends upon staging and may include chemotherapy, radiation, or stem cell transplant.
-
What Are the Stages of Chronic Lymphocytic Leukemia?
Chronic lymphocytic leukemia is a cancer of the blood and bone marrow. With this type of cancer, the marrow creates too many abnormal lymphocytes. There are five stages of chronic lymphocytic leukemia.
Treatment & Diagnosis
- Leukemia FAQs
- Evolution of Treatment for a Rare Type of Leukemia
- Gleevec and Chronic Myeloid Leukemia
- How Familes Cope with a Leukemia Diagnosis
- Coping with a Bad Disease - Community Counts
- A Family's Leukemia Diary - Coping
- Is Multiple Myeloma the Same as Leukemia?
- Does Folic Acid Prevent Leukemia?
- Can Folic Acid Prevent Leukemia?
- Chronic Myelogenous Leukemia (CML)
Medications & Supplements

QUESTION
What is leukemia? See AnswerHealth Solutions From Our Sponsors

Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.